Chimerix, Inc.'s CMX001 Resistance Data Presented at the 26th International Conference on Antiviral Research
5/16/2013 9:02:46 AM
More...
|
Chimerix, Inc. Announces First Quarter 2013 Financial Results
5/13/2013 9:32:38 AM
More...
|
Data on Chimerix, Inc.'s CMX001 Selected for Two Oral Presentations at the 26th International Conference on Antiviral Research
5/10/2013 9:17:57 AM
More...
|
Chimerix, Inc. to Announce First Quarter Financial Results on May 13, 2013
5/6/2013 9:21:52 AM
More...
|
Chimerix, Inc. Presents at Annual EBMT Meeting: Antiviral Activity of CMX001 in Patients With Life-Threatening Viral Infections
4/29/2013 11:36:39 AM
More...
|
Chimerix, Inc. to Present at the 12th Annual Needham Healthcare Conference
4/26/2013 11:33:11 AM
More...
|
Chimerix, Inc. Announces Final Study Design for Phase 3 SUPPRESS Trial of CMX001 for Prevention of CMV Infection
4/24/2013 11:41:33 AM
More...
|
Biotech Chimerix, Inc. Shines in IPO Debut as Interest Grows in Antiviral Drugs
4/23/2013 9:43:40 AM
More...
|
Chimerix, Inc. Sets Terms for $85 Million IPO
4/2/2013 8:46:35 AM
More...
|
Chimerix, Inc.'s Antiviral CMX001 Abstract Selected for an Oral Presentation at the European Group for Blood and Marrow Transplantation's Annual Meeting
3/28/2013 8:59:46 AM
More...
|
|